A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer.
The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study:
Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line [1L] PD-L1+ cohort).
Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line [2L] CIT-naive cohort).
Cohort 3 will consist of participants with locally-advanced or metastatic HR+, HER2-negative disease with PIK3CA mutation who may or may not have had disease progression during or following previous lines of treatment for metastatic disease (HR+cohort).
Cohort 4 will consist of participants with locally-advanced or metastatic HER2+ /HER2-low disease with PIK3CA mutation who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort).
In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). In addition, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.

开始日期2018-04-02

申办/合作机构

Hoffmann-La Roche, Inc.

[+2]

NCT03239145 / Active, not recruiting临床1期IIT

Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer.
The drugs involved in this study are:
Pembrolizumab
AMG386

开始日期2017-08-31

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+2]

NCT01907308 / Withdrawn临床2期IIT

A Phase II Single-arm Study of AMG 386 in Combination With Docetaxel for Advanced Urothelial Carcinoma After Failure of a Platinum-containing Regimen

This study plans to learn more about the combination of AMG 386 and docetaxel for the treatment of advanced urothelial cancer. Subjects are being asked to be in this research study because they have advanced urothelial cancer which has progressed after treatment with a platinum-based therapy.
The hypothesis is that AMG 386 will increase the historical response rate of docetaxel as a single agent.

开始日期2014-02-01

申办/合作机构

University of Colorado Denver

[+1]

100 项与 Trebananib 相关的临床结果

登录后查看更多信息

100 项与 Trebananib 相关的转化医学

登录后查看更多信息

100 项与 Trebananib 相关的专利（医药）

登录后查看更多信息

项与 Trebananib 相关的文献（医药）

2024-02-16·Clinical cancer research : an official journal of the American Association for Cancer Research

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Article

作者: Wilson, Amy ; Berry, Donald A ; Haddad, Tufia ; Blair, Sarah ; Stringer-Reasor, Erica ; Esserman, Laura J ; Euhus, David ; Symmans, W Fraser ; Lu, Janice ; Petricoin, Emanuel F ; Tripathy, Debu ; Boughey, Judy C ; Yau, Christina ; Wallace, Anne M ; Rugo, Hope S ; Forero-Torres, Andres ; Pusztai, Lajos ; Buxton, Meredith ; Melisko, Michelle ; Gallagher, Rosa I ; Perlmutter, Jane ; Hirst, Gillian L ; DeMichele, Angela M ; Wulfkuhle, Julia D ; Wolf, Denise M ; Chen, Yunn Yi ; Yee, Douglas ; Lang, Julie E ; Asare, Adam L ; Brown-Swigart, Lamorna ; Hylton, Nola M ; Chien, A Jo ; Elias, Anthony D ; Krings, Gregor ; Asare, Smita M ; Nanda, Rita ; Van't Veer, Laura J ; Potter, David A ; Albain, Kathy S ; Berry, Scott ; Yung, Rachel L ; Matthews, Jeffrey B ; Godellas, Constantine ; Singhrao, Ruby ; Sanil, Ashish ; Clennell, Julia L ; Kaplan, Henry ; Isaacs, Claudine ; Clark, Amy S

Abstract:

Purpose::

The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial.

Patients and Methods::

I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction.

Results::

There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease.

Conclusions::

The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.

2023-03-01·The Journal of pharmacology and experimental therapeutics

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

Article

作者: Depla, Erik ; Baum, Anke ; Gschwind, Andreas ; Hilberg, Frank ; Hofmann, Irmgard ; Künkele, Klaus-Peter ; Kraut, Norbert ; Budano, Nicole ; Hofmann, Marco H ; Trapani, Francesca ; Ebner, Florian ; Boucneau, Joachim ; Reichel-Voda, Claudia ; Sykora, Martina ; Aichinger, Martin ; Schweifer, Norbert ; Ehrensperger, Diane

Vascular endothelial growth factor (VEGF) and angiopoietin (ANG)-2 have complementary roles in angiogenesis and promote an immunosuppressive tumor microenvironment. It is anticipated that the combination of VEGF and ANG2 blockade could provide superior activity to the blockade of either pathway alone and that the addition of VEGF/ANG2 inhibition to an anti-programmed cell death protein-1 (PD-1) antibody could change the tumor microenvironment to support T-cell-mediated tumor cytotoxicity. Here, we describe the pharmacologic and antitumor activity of BI 836880, a humanized bispecific nanobody comprising two single-variable domains blocking VEGF and ANG2, and an additional module for half-life extension in vivo. BI 836880 demonstrated high affinity and selectivity for human VEGF-A and ANG2, resulting in inhibition of the downstream signaling of VEGF/ANG2 and a decrease in endothelial cell proliferation and survival. In vivo, BI 836880 exhibited significant antitumor activity in all patient-derived xenograft models tested, showing significantly greater tumor growth inhibition (TGI) than bevacizumab (VEGF inhibition) and AMG386 (ANG1/2 inhibition) in a range of models. In a Lewis lung carcinoma syngeneic tumor model, the combination of PD-1 inhibition with VEGF inhibition showed superior efficacy versus the blockade of either pathway alone. TGI was further increased with the addition of ANG2 inhibition to VEGF/PD-1 blockade. VEGF/ANG2 inhibition had a strong antiangiogenic effect. Our data suggest that the blockade of VEGF and ANG2 with BI 836880 may offer improved antitumor activity versus the blockade of either pathway alone and that combining VEGF/ANG2 inhibition with PD-1 blockade can further enhance antitumor effects. SIGNIFICANCE STATEMENT: Vascular endothelial growth factor (VEGF) and angiopoietin (ANG)-2 play key roles in angiogenesis and have an immunosuppressive effect in the tumor microenvironment. This study shows that BI 836880, a bispecific nanobody targeting VEGF and ANG2, demonstrates substantial antitumor activity in preclinical models. Combining VEGF/ANG2 inhibition with the blockade of the PD-1 pathway can further improve antitumor activity.

2022-04-01·World neurosurgery4区 · 医学

Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis

4区 · 医学

Article

作者: Tong, Chen ; Qian, Han ; Zhengyao, Zuo ; Fengqun, Mu ; Xiaozhuo, Liu ; Mei, Li ; Qing, Wang ; Mingming, Fan ; Dongpo, Su

BACKGROUND:

Despite the fact that bevacizumab (Bev) has been approved to treat recurrent glioblastoma, patients have failed to demonstrate a significant overall survival (OS) advantage. In recent years, the advent of more Bev combination regimens seems to bring new hope for patients; nevertheless, there is still a lack of intuitive comparison among these therapies.

OBJECTIVE:

To explore the efficacy and safety of various Bev combination regimens in patients with recurrent glioblastoma and to further explore the differences in the efficacy of each treatment in randomized controlled trials (RCTs) and nonrandomized controlled trials (non-RCTs).

METHODS:

We comprehensively searched the PubMed, Cochrane Library, and OVID databases for relevant RCTs and non-RCTs of Bev in combined regimens for recurrent glioblastoma. The Cochrane quality assessment method was used to assess the quality of RCTs, and the Newcastle-Ottawa scale was used to assess the quality of non-RCTs. Excel software was used to extract data from the literature, and a network meta-analysis was performed using RevMan 5.3 and Stata 16 statistical software.

RESULTS:

In patients with recurrent glioblastoma, the 6-month OS of patients receiving bevacizumab combination therapy was ranked from high to low as follows: Bev + rindopepimut, Bev + lomustine (CCNU), CCNU, tumor treating fields + Bev, Bev, Bev + irinotecan (Iri), Bev + temozolomide (TMZ), Bev + vorinostat, Bev + onartuzumab, Bev + dasatinib, Bev + carboplatin, Bev + trebananib, Bev + VB-111, TMZ, PCV, VB-111, and carboplatin. The 6-month progression-free survival from high to low was ranked as follows: Bev + CCNU, Bev + rindopepimut, Bev + dasatinib, Bev + vorinostat, Bev, Bev + Iri, Bev + TMZ, CCNU, Bev + carboplatin, TMZ, Bev + VB-111, PCV, Bev + trebananib, carboplatin, and VB-111. We compared the total incidence of serious adverse events (≥3) and found that Bev + vorinostat and Bev + trebananib were safer than Bev, while other regimens were not as safe as Bev. A descriptive analysis showed that Bev + rindopepimut also appeared to be safer than Bev. In subgroup analysis, among RCTs, Bev + CCNU therapy had the highest 6-month OS and 6-month progression-free survival. Among non-RCTs, Bev + Iri therapy showed the highest 6-month OS and good 6-month progression-free survival.

CONCLUSIONS:

Both Bev + CCNU and Bev + rindopepimut could be considered as effective therapies for treating the recurrent glioblastoma according to the network meta-analysis results. Among them, Bev + rindopepimut therapy seems to be safer and more effective. Moreover, we found that Bev + Iri also appeared to be an effective therapy in a retrospective study.

项与 Trebananib 相关的新闻（医药）

2024-03-23

·生物制品圈

抗体偶联药物治疗乳腺癌的研究进展

中文摘要抗体偶联药物（antibody-drug conjugate，ADC）是一类由单克隆抗体通过化学接头共价连接细胞毒性药物形成的新型生物治疗药物。ADC利用单克隆抗体将细胞毒性药物递送至肿瘤细胞，实现了对肿瘤细胞的精准杀灭，具有靶向性强和不良反应小的优势。美国FDA批准上市的15款ADC中，有3款用于治疗乳腺癌。此文主要对近年来应用于乳腺癌治疗的ADC的研究进展作一综述。正文2022年全球癌症登记数据显示，乳腺癌、肺癌和结直肠癌占所有新诊断女性癌症病例的51%，仅乳腺癌就占了31%。尽管化学治疗（化疗）、放射治疗和靶向治疗等多种治疗方式提高了乳腺癌的治愈率，并且延长了乳腺癌患者的总生存期（overall survival，OS），但由于上皮细胞-间充质转化和肿瘤干细胞呈现特殊细胞表型与代谢途径等多种肿瘤生物学特征，因此部分患者发生肿瘤易复发或易转移、甚至在多次治疗后耐药的情况。抗体偶联药物（anibody-drug conjugate，ADC）是一类相对较新的抗癌药物。理想的ADC由高特异性和高亲和力的单克隆抗体（单抗）、高稳定性的接头与高效的小分子细胞毒性药物（载荷）3部分组成。利用单抗的靶向特异性，药物被递送至表达特定目标抗原的肿瘤细胞，提高了治疗指数。截至2022年12月，全球共有15种ADC获批用于血液系统恶性肿瘤和实体肿瘤，其中3种ADC获批治疗乳腺癌，此外有超过100种候选ADC处于不同临床试验阶段。本文结合文献报道，综述治疗乳腺癌的ADC研究进展。1ADC简介1.1ADC的组成结构1.1.1 抗体理想的靶向肿瘤的抗体部分除了对目标抗原有高亲和力外，还应具备促进ADC有效内化的功能以及低免疫原性和较长的血浆半衰期。目前用于ADC的抗体大多是IgG，常用亚型是IgG1，这是因为IgG1在血清中含量最丰富，可通过与Fc受体的高亲和力诱导强大的效应功能，如抗体依赖细胞介导的细胞毒性（antibody-dependent cell-mediated cytotoxicity，ADCC）、抗体依赖性细胞介导的吞噬作用（antibody-dependent cellular phagocytosis，ADCP）和补体依赖的细胞毒性（complement-dependent cytotoxicity，CDC）。1.1.2 接头 ADC中的接头将抗体与细胞毒性药物连接，与ADC的稳定性和载荷释放曲线相关，对ADC的最终治疗指标很重要。理想的接头不应诱导ADC聚集，能限制血浆中载荷的过早释放，并促进其在所需靶点释放。根据在细胞中的代谢方式，大多数ADC使用的接头类型有2种：可裂解接头和不可裂解接头。可裂解接头利用体循环和肿瘤细胞之间的环境差异准确释放游离的载荷，分为化学可裂解接头（腙键和二硫键）和酶可裂解接头（葡糖苷酸键和肽键）。不可裂解的接头（如硫醚或马来酰亚胺基己酰基）对体内常见的化学和酶环境是惰性的，可提高ADC在血浆中的稳定性，且具有较低的脱靶毒性，但影响了载荷的旁观者效应。1.1.3 载荷载荷是在ADC内化进癌细胞后发挥细胞毒性的弹头。高效价的载荷（抑制中浓度在nmol/L和pmol/L范围内）是ADC研发的关键。此外，这些化合物应在生理条件下保持稳定，并具有与抗体结合的官能团。目前，用于ADC的载荷主要包括强效微管蛋白抑制剂、DNA损伤剂及免疫调节剂。ADC的结构组成及其主要功能见图1。1.2ADC的作用机制ADC的抗体部分与癌细胞上特异性表达的靶抗原结合，癌细胞通过内吞作用诱导ADC复合物内化而形成早期内体，随后成熟为晚期内体并与溶酶体融合。不可裂解接头通过ADC内化后在溶酶体内消化抗体的方式来释放载荷，载荷仍附着在接头和氨基酸残基上。可裂解接头的载荷释放是由切割位点的性质触发的，例如对pH敏感的腙接头在酸性条件下被水解；含有二硫键的接头在胞内高浓度的谷胱甘肽环境下被还原裂解；酶可裂解接头可被特定的酶降解从而释放载荷。这种针对癌细胞的选择性细胞毒性能显著减少全身不良反应。当释放的载荷具有渗透性或跨膜性时，还可能诱发旁观者效应以增强ADC的疗效。旁观者效应主要通过两方面增强ADC疗效：一方面，ADC释放的载荷可以直接从靶细胞扩散至周围的癌细胞并将其一同杀伤；另一方面，通过癌细胞释放与损伤相关的分子模式来促进肿瘤微环境中的免疫应答，从而进一步增强ADC的杀伤作用。一些ADC的抗体Fab段可与病毒感染细胞或肿瘤细胞的表位结合，Fc段可与效应细胞（如自然杀伤细胞、巨噬细胞等）表面的Fcγ受体结合，从而介导直接杀伤作用。此外，抗体部分可与癌细胞的抗原表位特异性结合，抑制抗原受体下游信号转导。例如，T-DM1中的曲妥珠单抗可与癌细胞上的人表皮生长因子受体（human epidermal growth factor receptor，HER）2结合阻断HER2与HER1、HER3或HER4之间异源二聚体的形成，抑制影响细胞存活和增殖的信号转导通路〔如磷脂酰肌醇3-激酶（phosphoinositide 3-kinase，PI3K）或丝裂原激活蛋白激酶〕，从而诱导细胞凋亡。ADC杀死癌细胞的作用机制见图2。2针对乳腺癌不同靶点的ADC用于乳腺癌治疗的ADC靶点除了经典的HER2靶点，还有人滋养细胞表面抗原2（trophoblast cell surface antigen 2，Trop2）、锌转运蛋白LIV-1、HER3等靶点陆续用于针对乳腺癌治疗的ADC研发中。表1总结了已上市的3款ADC以及部分处于临床阶段的ADC。以下将按照不同靶点对ADC进行介绍。2.1HER215%~20%的乳腺癌患者出现HER2过表达，同时HER2阳性乳腺癌侵袭性更高。2.1.1 T-DM1 T-DM1是第1个获得FDA批准用于HER2阳性乳腺癌临床治疗的ADC，由靶向HER2的曲妥珠单抗和抑制微管蛋白聚合的美坦辛衍生物（DM1）通过不可裂解的硫醚连接物连接而成，药物抗体比（drug-to-antibody ratio，DAR）约为3.5，即每个曲妥珠单抗平均携带3.5个DM1。Ⅲ期临床研究EMILIA显示，对于曲妥珠单抗和紫杉烷治疗失败的HER2阳性且不可切除、局部晚期（locally advanced，LA）或转移性乳腺癌（metastatic breast cancer，MBC）成年患者（n=911），T-DM1较拉帕替尼联合卡培他滨二线治疗可显著改善无进展生存期（progression-free survival，PFS）〔9.6比6.4个月；风险比（hazard ratio，HR）=0.65，P <0.000 1〕。同时，OS得到改善（29.9比25.9个月；HR=0.75，P <0.000 1），中位随访47.8个月。全球多中心的前瞻性随机对照研究KATHERINE共纳入1 486例患者，随机分配T-DM1或曲妥珠单抗治疗，与曲妥珠单抗治疗组相比，接受T-DM1治疗组的侵袭性无病生存期提高50%；3年后，接受T-DM1治疗的患者中88.3%没有复发，而接受曲妥珠单抗治疗的患者中77.0%没有复发。在一线治疗领域，MARIANNE试验显示，T-DM1（加用或不加用帕托珠单抗）治疗HER2阳性乳腺癌的PFS不劣于曲妥珠单抗加紫杉烷联合治疗。虽然还未确定优势，但这种新型联合疗法通常毒性较小。且T-DM1组的持续反应期为21个月，曲妥珠单抗加紫杉醇的持续反应期为12.5个月，T-DM1有更好的耐受性，可为患者提供更长的高质量生活期。2.1.2 T-Dxd 曲妥珠单抗-依沙替康衍生物也被称为DS-8201或T-Dxd，于2019年获批治疗既往已接受过2种以上HER2靶向疗法的不可手术切除或转移性HER2阳性乳腺癌患者。T-Dxd由靶向HER2的曲妥珠单抗与拓扑异构酶I抑制剂载荷Dxd通过可酶解的肽基接头偶联而成，DAR为8。Dxd在癌细胞中会诱导双链DNA断裂，最终导致癌细胞凋亡。T-Dxd的接头是可裂解的，进入癌细胞之后，Dxd就会与抗体解偶联，脂溶性的Dxd可以自由穿透脂质细胞膜，一并击杀周边HER2低表达的癌细胞，产生旁观者效应。由于这些独特的特性，T-Dxd比T-DM1对HER2表达低的癌症更有效。I期临床研究包括111例接受过多种治疗的晚期HER2阳性乳腺癌患者，T-Dxd单药治疗的有效率为59.5%，95%置信区间（confidence interval，CI）：49.7%~68.7%，中位有效期为20.7个月。DESTINY-Breast01临床研究中位随访11.1个月时，184例患者的队列总有效率为60.9%（95% CI：53.4%~68.0%），其中6%的患者出现完全缓解（complete response，CR），总疾病控制率（disease control rate，DCR）为97.3%（95% CI：93.8%~99.1%），中位至缓解时间为1.6个月（95% CI：1.4~2.6个月），表明T-Dxd有与经典化疗药物类似的快速抗癌活性。该研究在20. 5个月的随访后，仍有37例患者接受T-Dxd的治疗，缓解持续时间为20.8个月，中位PFS为19.4个月，中位OS为24.6个月，显示出T-Dxd在后线治疗中的出色疗效。前瞻性、随机对照、Ⅲ期临床研究DESTINY-Breast03（NCT03529110）入组524例HER2 阳性晚期二线乳腺癌患者，试验组接受T-Dxd，对照组接受T-DM1治疗；试验组和对照组中位PFS分别为28.8和6.8个月（HR=0.33，95% CI：0.47~0.87，P <0.000 01），OS差异也有统计学意义（HR =0.64，95% CI：0.47~0.87，P=0.003 7）。这些积极的结果使得T-Dxd成为HER2阳性晚期二线的标准治疗方案之一。2.1.3 SYD985 SYD985是在研的下一代抗HER2的ADC，用于HER2阳性不可切除的LA-MBC患者。SYD985由曲妥珠单抗与多卡霉素载荷通过可裂解接头连接组成，DAR为2.8。细胞毒性部分在内化后通过蛋白酶在细胞内溶酶体中切割成活性毒素，诱导DNA损伤，导致肿瘤细胞死亡。由于载荷是膜可渗透的，因此无论细胞HER2表达高低，载荷都有可能进入相邻细胞，通过旁观者效应提高疗效。2.2Trop2Trop2由TACSTD2基因编码，是一种用作细胞内钙信号转换器的跨膜糖蛋白。Trop2在多种上皮性肿瘤，包括尿路上皮癌、乳腺癌、妇科肿瘤、肺癌和胃肠道癌中过度表达。大多数实体瘤包括三阴性乳腺癌（triple-negative breast cancer，TNBC）中都能观察到Trop2的过表达。Trop2的过表达与强侵袭性和不良预后有关，这使得Trop2成为理想的广谱治疗靶点。TNBC是雌激素受体、孕激素受体和HER2均为阴性表达的乳腺癌亚型，由于TNBC不表达HER2，因此针对Trop2靶点的ADC研发日渐增多。2.2.1 IMMU-132 IMMU-132由抗Trop2单抗戈沙妥珠单抗通过可裂解的接头CL2A与拓扑异构酶I抑制剂SN-38偶联而成，具有较高的DAR（7.6），并且已在临床前研究中显示出对周围肿瘤组织的杀伤作用。在IMMU-132中，SN38是CPT-11的活性代谢物，通过抑制DNA拓扑异构酶I且造成频繁的DNA单链断裂导致细胞死亡。2020年4月，IMMU-132获得FDA的加速批准，用于治疗不能切除的LA或转移性TNBC患者，成为首个上市的Trop2靶向药物。ASCENT研究纳入了529例既往至少接受过2种化疗、进展复发的晚期TNBC患者，患者被随机分为2组，分别接受IMMU-132治疗（n=267，10 mg/kg）和单药化疗（n=262，卡培他滨/埃立布林/长春瑞滨/吉西他滨）。接受IMMU-132治疗的患者的中位PFS为4.8个月，而接受化疗的患者为1.7个月；IMMU-132组中位OS为11.8个月，而化疗组为6.9个月。2.2.2 DS-1062 DS-1062是包含拓扑异构酶I抑制剂Dxd的第2种Trop2靶向ADC，通过可裂解的基于四肽的接头与人源化抗Trop2 IgG1缀合，DAR为4。BEGONIA Ib/Ⅱ期临床试验（n=61）的最新结果显示，评估DS-1062联合度伐利尤单抗对既往未经治疗不可切除的LA或转移性TNBC 患者的ORR为73.6%（95% CI：59.7%~84.7%）。在53例可评估的患者中，有4例患者出现CR，35例出现部分缓解。无论患者的程序性死亡受体配体1表达情况如何（低表达和高表达肿瘤），都能观察到缓解。至2022年7月22日数据显示，82%的患者继续保持缓解。2022年11月，日本第一三共制药启动全球TROPION-Breast03 Ⅲ期临床试验（NCT05629585），评估DS-1062联合或不联合度伐利尤单抗用于新辅助治疗后有残留疾病的I~Ⅲ期TNBC患者。2.3LIV-1LIV-1属于跨膜锌转运蛋白家族，通常存在于激素调节的组织如乳腺中，其表达似对雌激素水平敏感。除乳腺癌外，LIV-1还在宫颈癌、子宫肿瘤、前列腺癌、胰腺癌以及黑色素瘤中被检测到。SGN-LIV1A由抗LIV-1人源化单抗通过可切割接头连接微管破坏剂组成，与表达LIV-1的细胞外结构域结合，并在内化后被运输到溶酶体，随后细胞毒性载荷通过蛋白酶水解释放。根据临床前模型，在TNBC中，SGN-LIV1A可以诱导有效的免疫原性细胞死亡，潜在地改善免疫治疗。目前正在对LIV-1阳性、不可切除、LA/MBC和TNBC患者进行I期临床试验（NCT01969643）。在第1次数据收集中，ORR为32%，在联合剂量递增和扩大队列（n=44）中治疗的TNBC患者的中位PFS为11.3周。2.4HER3HER3是HER家族的一员，由于没有或几乎没有细胞内的酪氨酸激酶活性，因此不能形成同源二聚体，只能与另一受体形成异源二聚体来诱导下游C端磷酸化。多种癌症，如头颈癌、结直肠癌、膀胱癌、黑色素瘤、肺癌、卵巢癌、前列腺癌和乳腺癌均过度表达HER3。HER3被认为与靶向疗法的耐药性有关，不仅是针对HER家族其他受体的疗法，还包括激素和PI3K抑制剂。此外，HER3体细胞突变也显示了一些致癌潜力。U3-1402是一种新型的抗HER3的ADC，由人源化抗HER3单抗通过可裂解的四肽接头与Dxd共价结合，DAR为8。临床研究数据截止时，在64例HER3高/雌、孕激素受体阳性/HER2阴性MBC患者中，6.4和4.8 mg/kg治疗组的ORR分别为30%和13%；在31例HER3低/雌、孕激素受体阳性/HER2阴性MBC患者和31例HER3高转移性TNBC患者中，ORR分别为33%（4.8 mg/kg）和16%（6.4 mg/kg）。3展望ADC的出现重塑了乳腺癌的治疗格局，将普通化疗升级为“精准化疗”，ADC巨大的临床治疗潜力将给乳腺癌患者带来新希望。但ADC研发道阻且长，现有的临床试验也在不断明晰ADC的定位，相关数据的补充将为进一步优化ADC结构提供基础，例如接头与载荷仍有进一步改进的空间，使其能更精准释放药物，同时降低毒性。目前乳腺癌领域先后上市的3款ADC都在各自Ⅲ期临床研究中取得了重大突破。除了HER2靶点，后续研发的靶向Trop2、LIV-1和HER3的ADC都取得了相关进展，如HER3-Dxd和SGN-LIV1A为雌、孕激素阳性/HER2阴性乳腺癌以及TNBC患者的生存获益提供了新的治疗选择和希望。此外，其他创新靶点研究也在进行中，最新研究表明，以细胞间黏附因子1为靶点的ADC在动物模型中能有效清除晚期和难治性TNBC，有望成为继Trop2后的具有临床潜力的TNBC ADC靶点。另外，不同靶点ADC能否序贯甚至联合使用来治疗乳腺癌也是未来值得探讨的方向。除了单药治疗，在联合治疗方面，研究人员将ADC和免疫检查点抑制剂（immune checkpoint inhibitor, ICI）的特性结合到单一化合物即免疫刺激抗体结合物中，这种化合物在小鼠模型中展现出强抗肿瘤免疫应答。研究表明，ADC-ICI疗法可能增强MBC患者的临床疗效及改善预后，这种双重疗法的多项试验已经在进行中。ADC联合治疗策略对于进一步提升临床疗效、克服ADC耐药性均具有重要意义。综上，ADC在肿瘤治疗领域具有十分广阔的应用前景，围绕ADC将会涌现出更多治疗模式和应用场景，从而为乳腺癌患者提供更精准、有效的治疗方案，推动乳腺癌治疗的进一步发展。作者梁明婵1 综述陈哲文2 审校1上海生物制品研究所有限责任公司第二研究室，上海 200051；2上海生物制品研究所有限责任公司，上海 201403通信作者：陈哲文，Email：13917843916@163.com引用本文：梁明婵, 陈哲文. 抗体偶联药物治疗乳腺癌的研究进展 [J]. 国际生物制品学杂志, 2024, 47(1): 56-62. DOI: 10.3760/cma.j.cn311962-20230508-00039识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

抗体药物偶联物放射疗法临床结果多肽偶联药物

2022-06-13

·PRNewswire

Fallopian Tube Cancer Therapeutics Market Size to Grow by USD 628.28 million | 39% of Market Growth to Originate from North America | Technavio

NEW YORK, June 13, 2022 /PRNewswire/ -- Fallopian tube cancer, also known as tubal cancer, is a type of cancer that is caused by an abnormal cell division in the fallopian tubes that connect to the ovaries and the uterus. It is a less common type of gynecologic cancer. The fallopian tube cancer therapeutics market size is expected to grow by USD 628.28 mn from 2021 to 2026. Moreover, the growth momentum of the market will accelerate at a CAGR of 9.06% during the forecast period. Technavio has announced its latest market research report titled Fallopian Tube Cancer Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026 Download an Exclusive Sample Report to learn more about market growth Top Key players in Fallopian Tube Cancer Therapeutics Market Amgen Inc. - The company offers fallopian tube cancer therapeutics, namely Trebananib. Baxter International Inc. - The company offers fallopian tube cancer therapeutics, namely Doxil. Bristol Myers Squibb Co. - The company offers fallopian tube cancer therapeutics, namely Opdivo. Clovis Oncology Inc. - The company offers fallopian tube cancer therapeutics, namely Rucaparib. Eli Lilly and Co. - The company offers fallopian tube cancer therapeutics, namely Gemzar. View an Exclusive Sample Report for a list of other key vendors operating in the market Market Trend and Challenge The growing research on regenerative therapies is driving the market growth. Various institutes and vendors are conducting research on developing novel regenerative therapies, including gene therapy, for the treatment of fallopian tube cancer. This, in turn, will fuel the fallopian tube cancer therapeutics market growth during the forecast period. Difficulty in diagnosis is challenging the fallopian tube cancer therapeutics market growth. The use of therapeutics may be carried out for long durations, which is a disadvantage for patients with late-stage fallopian tube cancer. This delay in diagnosis is resulting in an increased preference for alternative treatment options, such as surgeries. Market Segmentation Fallopian Tube Cancer Therapeutics Market Split by Product Targeted therapy: This segment will have the highest market share growth during the forecast period. The benefits of targeted therapy will drive the growth of the segment during the forecast period. Chemotherapy Fallopian Tube Cancer Therapeutics Market Split by Geography North America: The region will have the highest market share growth during the forecast period. This growth will be driven by factors such as the increasing adoption of therapeutics for the treatment of the indication. Moreover, market growth in this region will be faster than the growth of the market in other regions. Europe Asia Rest of World (ROW) Imperative Insights on the following aspects: What was the size of the global fallopian tube cancer therapeutics industry by value in 2020? What will be the size of the global fallopian tube cancer therapeutics industry in 2026? What factors are affecting the strength of competition in the global fallopian tube cancer therapeutics industry? How has the industry performed over the last five years? What are the main segments that make up the global fallopian tube cancer therapeutics market? Get lifetime access to our Technavio Insights! Subscribe to our "Basic Plan" billed annually at USD 5000 Why buy? Identify growth Strategies across markets Analyze your competitor market Know the financial performance of competitors with better insight Related Reports Payment Gateways Market by End-user and Geographic Landscape - Forecast and Analysis 2021-2025 Payment Gateways Market by End-user and Geographic Landscape - Forecast and Analysis 2021-2025 Table of Content: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Product 5.1 Market segments Exhibit 24: Chart on Product - Market share 2021-2026 (%) Exhibit 25: Data Table on Product - Market share 2021-2026 (%) 5.2 Comparison by Product Exhibit 26: Chart on Comparison by Product Exhibit 27: Data Table on Comparison by Product 5.3 Targeted therapy - Market size and forecast 2021-2026 Exhibit 28: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%) 5.4 Chemotherapy - Market size and forecast 2021-2026 Exhibit 32: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Product Exhibit 36: Market opportunity by Product ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Austria - Market size and forecast 2021-2026 Exhibit 62: Chart on Austria - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Austria - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Austria - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Austria - Year-over-year growth 2021-2026 (%) 7.9 China - Market size and forecast 2021-2026 Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%) 7.10 Switzerland - Market size and forecast 2021-2026 Exhibit 70: Chart on Switzerland - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Switzerland - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Switzerland - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Switzerland - Year-over-year growth 2021-2026 (%) 7.11 India - Market size and forecast 2021-2026 Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 Amgen Inc. Exhibit 85: Amgen Inc. - Overview Exhibit 86: Amgen Inc. - Product / Service Exhibit 87: Amgen Inc. - Key offerings 10.4 Baxter International Inc. Exhibit 88: Baxter International Inc. - Overview Exhibit 89: Baxter International Inc. - Business segments Exhibit 90: Baxter International Inc. - Key news Exhibit 91: Baxter International Inc. - Key offerings Exhibit 92: Baxter International Inc. - Segment focus 10.5 Bristol Myers Squibb Co. Exhibit 93: Bristol Myers Squibb Co. - Overview Exhibit 94: Bristol Myers Squibb Co. - Product / Service Exhibit 95: Bristol Myers Squibb Co. - Key offerings 10.6 Clovis Oncology Inc. Exhibit 96: Clovis Oncology Inc. - Overview Exhibit 97: Clovis Oncology Inc. - Business segments Exhibit 98: Clovis Oncology Inc. - Key offerings Exhibit 99: Clovis Oncology Inc. - Segment focus 10.7 Eli Lilly and Co. Exhibit 100: Eli Lilly and Co. - Overview Exhibit 101: Eli Lilly and Co. - Product / Service Exhibit 102: Eli Lilly and Co. - Key offerings 10.8 F. Hoffmann La Roche Ltd. Exhibit 103: F. Hoffmann La Roche Ltd. - Overview Exhibit 104: F. Hoffmann La Roche Ltd. - Business segments Exhibit 105: F. Hoffmann La Roche Ltd. - Key news Exhibit 106: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 107: F. Hoffmann La Roche Ltd. - Segment focus 10.9 GlaxoSmithKline Plc Exhibit 108: GlaxoSmithKline Plc - Overview Exhibit 109: GlaxoSmithKline Plc - Business segments Exhibit 110: GlaxoSmithKline Plc - Key news Exhibit 111: GlaxoSmithKline Plc - Key offerings Exhibit 112: GlaxoSmithKline Plc - Segment focus 10.10 ImmunoGen Inc. Exhibit 113: ImmunoGen Inc. - Overview Exhibit 114: ImmunoGen Inc. - Product / Service Exhibit 115: ImmunoGen Inc. - Key offerings 10.11 Johnson and Johnson Exhibit 116: Johnson and Johnson - Overview Exhibit 117: Johnson and Johnson - Business segments Exhibit 118: Johnson and Johnson - Key news Exhibit 119: Johnson and Johnson - Key offerings Exhibit 120: Johnson and Johnson - Segment focus 10.12 Merck and Co. Inc. Exhibit 121: Merck and Co. Inc. - Overview Exhibit 122: Merck and Co. Inc. - Business segments Exhibit 123: Merck and Co. Inc. - Key news Exhibit 124: Merck and Co. Inc. - Key offerings Exhibit 125: Merck and Co. Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 126: Inclusions checklist Exhibit 127: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 128: Currency conversion rates for US$ 11.4 Research methodology Exhibit 129: Research methodology Exhibit 130: Validation techniques employed for market sizing Exhibit 131: Information sources 11.5 List of abbreviations Exhibit 132: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Us: Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

基因疗法

100 项与 Trebananib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10177	-	-	DB12056

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
输卵管癌	临床3期	荷兰	Amgen, Inc.	2012-01-01
腹膜癌	临床3期	荷兰	Amgen, Inc.	2012-01-01
卵巢癌	临床3期	奥地利	Amgen, Inc.	2011-04-18
卵巢癌	临床3期	丹麦	Amgen, Inc.	2011-04-18
卵巢癌	临床3期	德国	Amgen, Inc.	2011-04-18
卵巢癌	临床3期	匈牙利	Amgen, Inc.	2011-04-18
卵巢癌	临床3期	新西兰	Amgen, Inc.	2011-04-18
卵巢癌	临床3期	新加坡	Amgen, Inc.	2011-04-18
卵巢癌	临床3期	斯洛伐克	Amgen, Inc.	2011-04-18
卵巢癌	临床3期	中国台湾	Amgen, Inc.	2011-04-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01664182 (CTgov)	临床2期	膀胱尿路上皮癌Ⅳ期 \| 晚期肾细胞癌 \| 非小细胞肺癌 III期	41	Trebananib (Arm I (Trebananib Monotherapy))	衊艱鏇構範願艱餘願鏇(糧襯蓋夢網構襯選鏇糧) = 壓簾願鏇遞簾鏇艱餘網衊壓艱糧憲積構鹽鏇艱 (艱積齋齋憲築網製觸廠, 鏇憲蓋蓋遞觸艱憲餘構 ~ 選膚構繭範構襯顧夢網) 更多	-	2022-06-07
				Bevacizumab+Sorafenib Tosylate+Trebananib+Sunitinib Malate+Pazopanib Hydrochloride (Arm II (Trebananib and Anti-VEGF Therapy))	衊艱鏇構範願艱餘願鏇(糧襯蓋夢網構襯選鏇糧) = 顧窪願選夢廠簾壓製醖衊壓艱糧憲積構鹽鏇艱 (艱積齋齋憲築網製觸廠, 壓夢獵顧網觸築鏇獵獵 ~ 壓構願遞膚憲糧鏇鹽觸) 更多
NCT00853372 (CTgov)	临床2期	转移性肾细胞癌 \| 晚期肾细胞癌	85	Trebananib+sunitinib (Trebananib 10 mg/kg + Sunitinib)	窪窪醖衊顧廠遞繭壓醖(窪鏇餘醖範窪遞構淵獵) = 淵範築築餘廠遞淵簾鏇餘鹹壓網鑰淵齋襯觸觸 (餘獵憲鹹醖鹽窪壓顧衊, 簾願艱淵膚壓繭顧鹹選 ~ 齋襯網衊繭鬱糧繭艱蓋) 更多	-	2020-07-01
				Trebananib+sunitinib (Trebananib 15 mg/kg + Sunitinib)	窪窪醖衊顧廠遞繭壓醖(窪鏇餘醖範窪遞構淵獵) = 鑰選齋網獵鑰遞壓鹹鏇餘鹹壓網鑰淵齋襯觸觸 (餘獵憲鹹醖鹽窪壓顧衊, 顧繭夢廠襯築鹽醖遞積 ~ 膚製遞夢獵繭鏇糧憲築) 更多
NCT01493505 (TRINOVA-3, Pubmed \| Lancet Oncol) 人工标引	临床3期	卵巢癌一线	1,015	carboplatin+paclitaxel+Trebananib	願積網壓構鬱鬱窪鹹簾(願窪築壓獵製壓衊蓋選) = 餘觸鹽膚範網選繭餘願襯憲夢範簾窪餘糧鹹鏇 (廠夢製鏇積範鹽蓋醖餘 ) 更多	不佳	2019-06-01
				carboplatin+paclitaxel+Placebo	願積網壓構鬱鬱窪鹹簾(願窪築壓獵製壓衊蓋選) = 鏇獵顧簾簾簾願窪願夢襯憲夢範簾窪餘糧鹹鏇 (廠夢製鏇積範鹽蓋醖餘 ) 更多
NCT03239145 (ASCO2019) 人工标引	临床1期	结直肠癌	18	trebananib+pembrolizumab	蓋繭鬱構鹹廠遞襯廠顧(醖遞鏇鑰簾願簾簾鬱淵) = None 廠鹹餘窪鹹觸鹹膚積憲 (醖鑰衊餘糧製鑰夢壓憲 ) 更多	积极	2019-05-31
NCT01664182 (Pubmed) 人工标引	临床2期	肾细胞癌二线	35	Trebananib	窪襯壓糧繭艱觸構簾廠(鹽獵願願獵艱觸齋齋餘) = 夢衊廠構網構範糧膚憲餘積製膚醖廠構獵膚構 (壓鏇憲衊醖窪範淵夢鬱, 2.3 ~ 4.7)	不佳	2019-02-05
				anti-VEGF agent+Trebananib (AMG 386)	窪齋壓糧夢艱窪遞顧繭(餘夢醖積夢獵糧淵蓋鑰) = 簾網淵膚糧襯選願鑰鏇餘艱糧衊獵鹽鏇積齋構 (襯獵鹽鹹窪衊製簾構範, 1 ~ 35) 更多
NCT01553188 (CTgov)	临床2期	转移性去势抵抗性前列腺癌 \| 晚期前列腺癌	36	Prednisone+Abiraterone+AMG 386 (Abiraterone, Prednisone and AMG)	遞艱餘壓簾壓襯鏇淵遞(壓憲淵製廠網築餘壓蓋) = 憲範鹽鬱壓願憲鑰鬱鑰憲網築膚夢憲觸鹹繭蓋 (壓積製艱餘鏇蓋製膚觸, 窪糧遞襯遞廠窪願糧鹽 ~ 繭願餘願鏇製糧壓鹹憲) 更多	-	2018-10-16
				Prednisone+Abiraterone (Abiraterone and Prednisone Only)	遞艱餘壓簾壓襯鏇淵遞(壓憲淵製廠網築餘壓蓋) = 襯積遞餘願夢夢齋糧糧憲網築膚夢憲觸鹹繭蓋 (壓積製艱餘鏇蓋製膚觸, 憲遞糧製願餘鹹積遞齋 ~ 選製襯網蓋醖淵鏇餘窪) 更多
NCT00872014 (Pubmed)	临床2期	晚期肝细胞癌一线	60	Trebananib 10 mg/kg	鏇範顧範襯膚觸範壓鹹(積選蓋齋淵餘積鑰鬱壓) = 鬱築繭鬱淵繭獵衊淵壓壓積鬱願構簾齋鑰積願 (夢範鹽餘蓋蓋膚襯獵鹽 ) 更多	不佳	2017-07-01
				Trebananib 15 mg/kg	鏇範顧範襯膚觸範壓鹹(積選蓋齋淵餘積鑰鬱壓) = 夢壓顧醖蓋餘糧夢襯蓋壓積鬱願構簾齋鑰積願 (夢範鹽餘蓋蓋膚襯獵鹽 ) 更多
NCT01290263 (CTgov)	临床1/2期	多形性胶质母细胞瘤 \| 复发性胶质母细胞瘤	48	Bevacizumab+AMG 386 (All Cohort B Participants: AMG 386 + Bevacizumab)	觸鬱構鹹鹽築構築膚餘(積壓餘餘艱顧鏇簾製繭) = 遞廠襯鑰膚鏇餘淵積憲糧築憲衊鏇糧蓋蓋艱襯 (簾襯築鏇築齋鑰鑰願醖, 簾廠鹽廠齋淵簾餘衊願 ~ 窪網願窪鏇淵艱觸積選) 更多	-	2017-05-25
				AMG 386 (Cohort A: AMG 386 30 mg/kg)	觸鬱構鹹鹽築構築膚餘(積壓餘餘艱顧鏇簾製繭) = 繭艱窪願壓範壓鬱範範糧築憲衊鏇糧蓋蓋艱襯 (簾襯築鏇築齋鑰鑰願醖, 簾網願繭鏇鏇窪鑰製簾 ~ 觸網構餘願構鏇蓋構鹽) 更多
NCT01609790 (NRG/RTOG 1122, CTgov)	临床2期	神经胶质肉瘤 \| 少突神经胶质瘤 \| 复发性胶质母细胞瘤	137	Bevacizumab+AMG 386 (Safety Run-In)	糧獵積鏇願構鑰糧鬱繭(願鏇糧齋膚製築衊齋築) = 衊憲顧醖顧膚觸鬱網簾鑰鑰蓋鹽壓觸醖繭鏇構 (廠鬱醖鹹積鬱觸願壓膚, 鏇製壓膚糧膚淵襯網積 ~ 夢艱糧鏇膚觸壓蓋簾壓) 更多	-	2017-02-27
				Placebo+Bevacizumab (Cohort 2: Bevacizumab+Placebo)	壓鏇鏇餘襯獵壓積襯壓(鑰鹹顧獵壓襯夢鹽淵糧) = 壓蓋簾艱糧觸積憲艱鬱餘壓蓋鹹範淵觸鏇壓鹹 (憲網餘憲壓選簾蓋構齋, 壓築窪鏇構選艱壓築蓋 ~ 築廠製艱襯淵鑰壓獵繭) 更多
NCT01281254 (ENGOT-ov-6 \| TRINOVA-2, Pubmed \| Eur J Cancer) 人工标引	临床3期	卵巢癌	223	pegylated liposomal doxorubicin+trebananib	繭艱衊築鹹鹽憲糧鹽淵(顧壓衊廠鹹遞鹹觸夢築) = 簾襯憲夢廠艱觸膚齋憲鏇夢鬱顧齋築鑰衊醖夢 (膚簾製蓋衊積觸積鬱鑰, 7.2 ~ 9.0) 更多	不佳	2017-01-01
				pegylated liposomal doxorubicin+Placebo	繭艱衊築鹹鹽憲糧鹽淵(顧壓衊廠鹹遞鹹觸夢築) = 鏇製繭衊夢遞糧齋構範鏇夢鬱顧齋築鑰衊醖夢 (膚簾製蓋衊積觸積鬱鑰, 4.8 ~ 8.2) 更多